Literature DB >> 18650070

Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.

Joon Young Song, Jacob Lee, Jung Yeon Heo, Ji Yun Noh, Woo Joo Kim, Hee Jin Cheong, In Sook Hwang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18650070     DOI： 10.1016/j.ijantimicag.2008.04.013

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  16 in total

1.  Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection.

Authors:  Qi Tony Zhou; Thomas Gengenbach; John A Denman; Heidi H Yu; Jian Li; Hak Kim Chan
Journal:  AAPS J       Date:  2013-10-16       Impact factor: 4.009

2.  Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.

Authors:  G Kalin; E Alp; A Akin; R Coskun; M Doganay
Journal:  Infection       Date:  2013-07-05       Impact factor: 3.553

Review 3.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

4.  Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.

Authors:  Wenbo Wang; Qi Tony Zhou; Si-Ping Sun; John A Denman; Thomas R Gengenbach; Nicolas Barraud; Scott A Rice; Jian Li; Mingshi Yang; Hak-Kim Chan
Journal:  AAPS J       Date:  2015-11-24       Impact factor: 4.009

Review 5.  Colistin in the 21st century.

Authors:  Roger L Nation; Jian Li
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

Review 6.  Multidrug-resistant Gram-negative infections: what are the treatment options?

Authors:  Helen Giamarellou; Garyphallia Poulakou
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

7.  Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture.

Authors:  Yung-Chih Wang; Shu-Chen Kuo; Ya-Sung Yang; Yi-Tzu Lee; Chun-Hsiang Chiu; Ming-Fen Chuang; Jung-Chung Lin; Feng-Yee Chang; Te-Li Chen
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

8.  Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; Navneet Singh; Narayan Mishra; G C Khilnani; J K Samaria; S N Gaur; S K Jindal
Journal:  Lung India       Date:  2012-07

9.  Renal and neurological side effects of colistin in critically ill patients.

Authors:  Herbert Spapen; Rita Jacobs; Viola Van Gorp; Joris Troubleyn; Patrick M Honoré
Journal:  Ann Intensive Care       Date:  2011-05-25       Impact factor: 6.925

10.  In vitro Comparison of Anti-Biofilm Effects against Carbapenem-Resistant Acinetobacter baumannii: Imipenem, Colistin, Tigecycline, Rifampicin and Combinations.

Authors:  Joon Young Song; Hee Jin Cheong; Ji Yun Noh; Woo Joo Kim
Journal:  Infect Chemother       Date:  2015-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.